Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
Brief Summary: This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a potential treatment to be used in conjunction with drug desensitization to prevent reactions from recurring and allowing the participant to be treated with the chemotherapy the participant's oncologist prefers to give.